End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
41.5 THB | -1.19% | +1.22% | -1.19% |
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- Considering the small differences between the analysts' various estimates, the group's business visibility is good.
Weaknesses
- With a 2024 P/E ratio at 25.36 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
- The company appears highly valued given the size of its balance sheet.
- The company is highly valued given the cash flows generated by its activity.
Ratings chart - Surperformance
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-1.19% | 254M | - | ||
-31.29% | 12.6B | B+ | ||
+5.14% | 11.8B | B+ | ||
-5.41% | 11.48B | B | ||
+12.01% | 10.98B | B+ | ||
+28.75% | 8.54B | B | ||
+18.63% | 7.36B | B- | ||
-10.66% | 7.22B | A- | ||
+7.33% | 6.54B | D | ||
0.00% | 4.44B | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
- Stock Market
- Equities
- KLINIQ Stock
- Ratings Thai NVDR Co., Ltd.